Outcomes of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma Treated with Aggressive Chemotherapy
A Phase 2, Open Label, 2-Cohort, Multi-center Study of INCB50465, a P13K Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with or Without a BTK Inhibitor
Phase 1b/2, Open Label, study of Alcalabrutinib alone or in combination with Rituximab in subjects with Indolent B-Cell, Non-Hodgkins Lymphoma (MZL)